Cours suspendu

Communiqués Crinetics Pharmaceuticals

Actions

CRNX

US22663K1079

Marché Fermé - Nasdaq 22:00:00 31/08/2026			Varia. 5j.	Varia. 1 janv.
84,95 ^USD	+0,13%		+0,13%	+82,49%

01/09	Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX) a finalisé l'acquisition de Crinetics Pharmaceuticals, Inc. (NasdaqGS:CRNX) auprès d'un groupe d'actionnaires.	CI
01/09	Vertex Pharmaceuticals finalise l'acquisition de Crinetics Pharmaceuticals	MT

Communiqués

17/08	Crinetics Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Crinetics Pharmaceuticals, Inc. - CRNX	BU
03/08	Crinetics Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update	GL
08/07	Crinetics Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Crinetics Pharmaceuticals, Inc. - CRNX	BU
07/07	SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Crinetics Pharmaceuticals, Inc. (CRNX)	NE
30/06	Crinetics Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 4, 2026	GL
14/06	Crinetics Presents Full Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH) in Oral Presentation at ENDO 2026	GL
14/06	Crinetics Presents Long Term Data at ENDO 2026 Confirming PALSONIFY™ (paltusotine) Provides Durable, Consistent Acromegaly Control	GL
03/06	Crinetics Paradigm-Shifting Portfolio and Pipeline on Display at ENDO 2026 with Six Presentations	AQ
02/06	Crinetics and Leading Patient Groups Launch ‘Everyday Advocacy’ Initiative to Empower People Across Endocrine Disease Communities	GL
02/06	Crinetics’ Paradigm-Shifting Portfolio and Pipeline on Display at ENDO 2026 with Six Presentations	GL
22/05	Crinetics Pharmaceuticals to Participate in Jefferies Global Healthcare Conference 2026	GL
08/05	Crinetics Pharmaceuticals : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q)	PU
07/05	Crinetics Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update	GL
07/05	Crinetics Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update	AQ
27/04	Crinetics Pharmaceuticals Announces the European Commission Approval of PALSONIFY® (Paltusotine) for the Treatment of Acromegaly in Adults	GL
16/04	Crinetics Pharmaceuticals : Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update	PU
16/04	Crinetics Pharmaceuticals : Announces Submission of Marketing Authorization Application in Brazil for Palsonify™ (Paltusotine) in Acromegaly	PU
08/04	Crinetics Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026	GL
26/03	Crinetics Pharmaceuticals Announces Submission of Marketing Authorization Application in Brazil for Palsonify™ (Paltusotine) in Acromegaly	GL
26/02	Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update	GL
26/02	Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update	AQ
05/02	Crinetics Pharmaceuticals to Participate in Two Upcoming Investor Conferences in March	GL
26/01	Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026	GL
22/01	Crinetics Initiates Phase 2/3 Pediatric Trial Evaluating Atumelnant in Congenital Adrenal Hyperplasia (CAH)	GL
12/01	Crinetics Pharmaceuticals Announces January 2026 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	GL